PTO

06-07-01

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **RB-125 SEQ**

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility pate	nt application for an				
nvention entitled:	AND METHOD				
NUCLEIC ACID SEQUENCES ENCODING TYPE III TENEBRIO ANTIFREEZE PROTEINS	AND METHOD				
FOR ASSAYING ACTIVITY	96 96 1				
and invented by:	s				
Kathleen L. Horwath et al.	JC872 U 09/87				
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information	on:				
Continuation Divisional Continuation-in-part (CIP) of prior application N Which is a:	o.:				
Continuation Divisional Continuation-in-part (CIP) of prior application N	0.:				
Wgich is a:					
Continuation Divisional Continuation-in-part (CIP) of prior application N	o.:				
Englosed are:					
Application Elements					
Application Elements 1.					
2. Specification having pages and including the following:					
a. Descriptive Title of the Invention					
b. Cross References to Related Applications (if applicable)					
c. Statement Regarding Federally-sponsored Research/Development (if applicable)	ole)				
d. Reference to Microfiche Appendix (if applicable)					
e. 🗷 Background of the Invention					
f. 🗵 Brief Summary of the Invention					
g. 🗵 Brief Description of the Drawings (if drawings filed)					
h. 🗵 Detailed Description					
i. 🗵 Claim(s) as Classified Below					
j. 🗷 Abstract of the Disclosure					

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RB-125 SEQ

Total Pages in this Submission

Application Elements (Continued)

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)						
	a.	Formal b. Informal Number of Sheets 131						
4.	X	☑ Oath or Declaration						
	a.	Newly executed (original or copy) □ Unexecuted						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)						
	c. 🗵 With Power of Attorney 🔲 Without Power of Attorney							
2000	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
6 .		Computer Program in Microfiche						
2 .	X	Genetic Sequence Submission (if applicable, all must be included)						
	a.	. 🗷 Paper Copy						
	b.	☑ Computer Readable Copy						
c. 🗵 Statement Verifying Identical Paper and Computer Readable Copy								
	Accompanying Application Parts							
8.		Assignment Papers (cover sheet & documents)						
9.		37 CFR 3.73(b) Statement (when there is an assignee)						
10.		English Translation Document (if applicable)						
11.		Information Disclosure Statement/PTO-1449						
12.		Preliminary Amendment						
13.	X	Acknowledgment postcard						
14.	X	Certificate of Mailing						
		☐ First Class ☒ Express Mail (Specify Label No.): EL184397198US						

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RB-125 SEQ

Total Pages in this Submission

		Accompanying Application Parts (Continued)	
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)	
16.	X	Not required Applicant claims Small Entity Statement(s) ->Specify:Number of Statements:Submitted: small entity status	
17.		Additional Enclosures (please identify below):	

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. RB-125 SEQ

Total Pages in this Submission

Fee Calculation and Transmittal

يختثو		CLAIMS	AS FILED		
For	#Filed	#Allowed	#Extra	Rate	Fee
Гotal Claims	40	- 20 =	20	x \$9.00	\$180.00
ក្សា ndep. Claims	11	- 3 =	8	x \$40.00	\$320.00
्रा Mæltiple Depender	nt Claims (check	if applicable)			\$0.00
Table 1				BASIC FI	EE \$355.00
OTHER FEE (spe	cify purpose)				\$0.00
15 15 15 15 15 15 15 15 15 15 15 15 15 1				TOTAL FILING FI	EE \$855.00
 ☑ Charge the amount of \$855.00 as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Motice of Allowance, pursuant to 37 C.F.R. 1.311(b). Dated:					
	- 1 / 1)		V	Signature	

cc:

Applicant(s): Kathleen I	MAIL" (37 CFR 1.10)	Docket No. RB-125 SEQ				
Serial No. Serial No. Propertion: NUCLEIC A	Filing Date	Examiner	Group Art Unit			
ention: NUCLEIC A		TYPE III TENEBRIO ANTIFREE	ZE PROTEINS			
I hereby certify that this Patent Application, Sequence Listings, Formal Papers, Drawings, Postcard (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.						
20231-0001 on	June 7, 2001 (Date)	(Typed or Printed Name of Person Mailing Constitute of Person Mailing Constitute of Person Mailing Constitute of Person Mailing Constitute of Person Mailing Land ("Express Mail" Mailing Land Person Mailing Constitution Person P	US			

Note: Each paper must have its own certificate of mailing.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kathleen L. Horwath et al.

Examiner:

Serial No.: (not yet assigned)

Group No.:

Filed: June 7, 2001

Date: June 7, 2001

Title: NUCLEIC ACID SEQUENCES ENCODING TYPE III TENEBRIO
ANTIFREEZE PROTEINS AND METHOD FOR ASSAYING ACTIVITY

Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING" AND COMPUTER READABLE COPY

Sir/Madame:

Submitted herewith are:

- A. "Sequence Listings" for the nucleotide and/or amino acid sequences in this application, each "Sequence Listing" is assigned a separate identifier as required in 37 CFR Sections 1.821(c) and 37 CFR Sections 1.822 and 1.823;
- B. A copy of each "Sequence Listing" submitted for this application in computer readable form in accordance with the requirements of 37 CFR Sections 1.821(e) and 1.824;
- C. The following statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same as required in 37 CFR Section 1.821(f).

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

By:

Mark Levy
Reg. No. 29,188
Attorney for Applicants
SALZMAN & LEVY
Press Building, Ste. 902
19 Chenango St.
Binghamton, NY 13901

CERTIFICATE OF EXPRESS MAILING